News
GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma
GV20 received an upfront payment and is eligible for additional milestone payments
- By IPP Bureau
| November 28, 2025
GV20 Therapeutics (GV20), a clinical-stage biotech pioneering AI-powered cancer therapies, has announced that it has received a milestone payment under its collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC).
The partnership, launched in early 2025, leverages GV20’s proprietary STEAD AI platform to develop potentially first-in-class antibody-drug conjugates (ADCs) targeting novel tumor antigens.
"We are pleased to reach this important milestone in our partnership with MTPC," said Ying Gong, Chief Business Officer of GV20. "This progress reflects our shared commitment to rapidly advancing innovative ADC therapies for patients with cancer. We look forward to continuing this positive momentum."
Under the collaboration, GV20 received an upfront payment and is eligible for additional milestone payments, while MTPC holds an exclusive right to negotiate a license for the antibodies during the term of the agreement.
GV20 is known for integrating massive B cell repertoire data, -omics datasets, and advanced AI modeling to uncover therapeutic antibodies that evade traditional discovery methods. Its pipeline includes both best-in-class and first-in-class monoclonal and bispecific antibodies, as well as ADCs.
